Tuba City Regional Health Care Corporation

CollPlant, Tel Aviv University and Sheba Medical Center Join Forces to Co-Develop rhCollagen-Based 3D Bioprinted Human Intestine Model for Drug Discovery and Personalized Treatment of Ulcerative Colitis

Retrieved on: 
Tuesday, November 15, 2022
Transfer, Perception, Doctor of Philosophy, Intellectual property, Tuba City Regional Health Care Corporation, SEC, Ramot at Tel Aviv University, 3D, Technology, Allergan, MD, Patient, Colitis, Forward-looking statement, Harvard University, Annual report, City, Wyss Institute, Risk, Genetic engineering, Industry, 3D bioprinting, Company, Newsweek, 3D Systems, Ulcerative colitis, Terminology, Tissue, Sheba Medical Center, Research, Marketing, Pediatric gastroenterology, COVID-19, CEO, NASDAQ, Form 20-F, Inflammatory bowel disease, Wyss Institute for Biologically Inspired Engineering, Hospital, Drug discovery, Inflammatory Bowel Diseases, Clinical trial, AbbVie, Bio-ink, Drug development, Disease, Tel HaShomer, Public expenditure, Medical imaging, Pharmaceutical industry, Medical device, Tel Aviv University

Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.

Key Points: 
  • Designed to emulate the human intestine tissue, the 3D bioprinted model will allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes.
  • Kit Parker at the Wyss Institute at Harvard University, Dr. Yael Haberman from the Pediatric Gastroenterology unit of Sheba Medical Center, and CollPlant's team of scientists and engineers.
  • "We are excited to embark on this important collaboration with Tel Aviv University and Sheba Medical Center for what will represent CollPlant's strategic expansion into personalized medicine.
  • About Ramot and Tel Aviv University:
    Ramot is the technology transfer company ofTel Aviv University, one ofIsrael'sforemost research and teaching universities.

First-Ever National Permit to Operate Autonomous Electric Buses Awarded to Imagry

Retrieved on: 
Monday, November 7, 2022
Sheba Medical Center, Hospital, Investment, Israel Innovation Authority, City, Accident, Air pollution, Tuba City Regional Health Care Corporation, Transport, CEO, Pedestrian, Nateev Express, Engineering, AD, Newsweek, Technology, Solution, Road, Satellite navigation device

HAIFA, Israel, Nov. 7, 2022 /PRNewswire/ -- The Israel Innovation Authority announced today that Imagry, a developer of mapless autonomous driving technology, has received approval to operate the first public buses with AD capability using its novel platform in the city of Nahariya, Israel. Imagry is an Israeli start-up company, founded in 2015. For the past four years Imagry has been operating vehicles equipped with its autonomous driving software on public roads in the United States, Germany, and Israel. Imagry will install its system on electric buses operated by Nateev Express, one of the largest public transportation providers in the country.

Key Points: 
  • For the past four years Imagry has been operating vehicles equipped with its autonomous driving software on public roads in the United States, Germany, and Israel.
  • Imagry will install its system on electric buses operated by Nateev Express, one of the largest public transportation providers in the country.
  • "We are pleased to meet the challenge to operate the first autonomous buses on public roads in Israel," states Eran Ofir, CEO of Imagry.
  • Imagry currently operates autonomous vehicles on public roads in California, Arizona, Haifa, and Frankfurt.

GATC Health Appoints Medical AI Veteran Robert Keith Sorrentino, MD as Chief Medical Officer

Retrieved on: 
Thursday, August 25, 2022
Statistics, Navajo, Machine learning, Massachusetts Institute of Technology, Conditional sentence, Fred Brooks, Technology, Watson (computer), ACM, Emergency medicine, Artificial intelligence, View, Time, Durrow healthcare consultancy, Physics, Informatics, DARPA, MIT, Health, Navajo Nation, Science, Multimedia, Renaissance School of Medicine at Stony Brook University, Harvard University, College of Arts and Sciences, Medicine, Database, Leadership, Tuba City Regional Health Care Corporation, Company, Biotechnology, Cedars-Sinai Medical Center, Stony Brook University, ACHE, UCLA, Association, Risk, Big data, Drug discovery, Growth, Human body, AI, Marketing, American College, CMO, Medical device, Hospital, MD

IRVINE, Calif., Aug. 25, 2022 /PRNewswire/ -- GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced Robert Keith Sorrentino, MD, as Chief Medical Officer.

Key Points: 
  • IRVINE, Calif., Aug. 25, 2022 /PRNewswire/ -- GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced Robert Keith Sorrentino, MD, as Chief Medical Officer.
  • GATC Health, a science and technology company utilizing AI for drug discovery, appoints Dr. Sorrentino as CMO
    Before joining GATC Health, Dr. Sorrentino previously founded and served as chief executive officer of AI for Healthcare Consultants, a consulting firm focused on serving novel technology companies that utilize AI and machine learning for clinical services and pharmaceutical development.
  • "Dr. Sorrentino has been a fundamental addition to the GATC Health team over the last several months as a consultant, and we are beyond thrilled to officially welcome him to the team as our Chief Medical Officer," said Jeff Moses, President of GATC Health.
  • "The innovative AI technology, dedicated leadership and sheer potential of GATC Health is unrivaled in this space," said Dr. Sorrentino.

Nuvo Group and Sheba Medical Center's "Sheba BEYOND" Complete First Phase of Collaboration to Create a Virtual Obstetric Solution & Catalyze Research to Advance the Standard of Pregnancy Care

Retrieved on: 
Wednesday, August 17, 2022
FDA, Woman, Multimedia, Fast Company, Industry, CEO, Tel HaShomer, Technology, Pregnancy, Telehealth, CB Insights, Obstetrics, Top Ten, Research, Health, Sheba Medical Center, Gestational diabetes, Patient, Academic health science centre, TEL, View, Program, Parent, Partnership, Tuba City Regional Health Care Corporation, Nuvo, Thought, Physician, Goal, NEWSWEEK, Digital, Solution, Mother, Heart, Medicine, Contraindication, City, INVU, Medical device, Online shopping

TEL AVIV, Israel, Aug. 17, 2022 /PRNewswire/ -- Nuvo Group—the creators of INVU by Nuvo™, an FDA-approved remote pregnancy monitoring platform—announced today that it has completed the first phase of its collaboration agreement with Israel's Sheba Medical Center's "Sheba BEYOND", one of the Top Ten medical centers in the world (NEWSWEEK) and a global leader in biotechnological innovation.

Key Points: 
  • Participating physicians prescribed INVU to expectant mothers, who wore the sensor band from home during virtual visits.
  • For the next phase of the partnership, Nuvo and Sheba intend to work together to integrate the INVU platform into the hospital's standard of care protocols.
  • The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation.
  • Sheba BEYOND is the medical center's innovative virtual hospital, which offers a myriad of technological solutions for advanced patient care.

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Retrieved on: 
Wednesday, July 6, 2022
American Society of Clinical Oncology, Decision-making, Patient, Research, Macrophage, GLOBE, Marketing, General officer, Progression-free survival, Phase, U.S. Securities and Exchange Commission, Tel Aviv University, Immune system, Animal, Oncology, Primary tumor, International Society, ASCO, Therapy, Security (finance), MFD, Department, FDA, Tuba City Regional Health Care Corporation, Annual general meeting, Tissue, TEL, Sheba Medical Center, Population, Risk, Newsweek, Immunotherapy, Sepsis, ORR, Cell, Technology, Private Securities Litigation Reform Act, Survival, Nasdaq, SOC, City, Ascites, Annual report, Abdomen, Surgical oncology, Metastasis, Cancer, Principal, Intraperitoneal injection, Human, Gene, Tumor microenvironment, Safety, Peritoneum, Society, Hope, Pharmaceutical industry, Medical imaging, Medical device

Patients with peritoneal metastases are in urgent need of novel treatment options, as standard-of-care (SOC) chemotherapy currently provides only modest survival benefits.

Key Points: 
  • Patients with peritoneal metastases are in urgent need of novel treatment options, as standard-of-care (SOC) chemotherapy currently provides only modest survival benefits.
  • We are eager to test this new combination with the hope of changing the lives of patients with peritoneal metastases.
  • We are excited to test this combination as a new hope for patients with peritoneal cancers.
  • It is designed to evaluate the safety and potential preliminary efficacy of Allocetra combined with SOC chemotherapy in patients with peritoneal metastases arising from solid cancer.

ZEUS Scientific Acquires Synthetic Peptides from Sheba Medical Center's Tech Transfer Co.

Retrieved on: 
Friday, October 29, 2021
Transfer, Sheba Medical Center, CFR, Peptide, Diagnosis, Technology, Research, City, US, Industry, Autoantibody, Invention, FDA, Degenerative disease, Tuba City Regional Health Care Corporation, TTO, Infection, Chief innovation officer, CEO, Epitope, Inflammation, Awareness, Joint, Therapy, RA, IVD, GLOBE, Tel HaShomer, Service, Infrastructure in Warsaw, Fine chemical, Medical device

BRANCHBURG, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- ZEUS Scientific has obtained exclusive, worldwide rights to the use of these synthetic peptides as targets of disease-specific autoantibodies in Rheumatoid Arthritis (RA) from Sheba Medical Center's, Tel Hashomer Medical Research, Infrastructure and Services Ltd. (Tel Hashomer Ltd.) the hospital's Technology Transfer Company (TTO).

Key Points: 
  • BRANCHBURG, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- ZEUS Scientific has obtained exclusive, worldwide rights to the use of these synthetic peptides as targets of disease-specific autoantibodies in Rheumatoid Arthritis (RA) from Sheba Medical Center's, Tel Hashomer Medical Research, Infrastructure and Services Ltd. (Tel Hashomer Ltd.) the hospital's Technology Transfer Company (TTO).
  • The inventors, Professor Howard Amital, Professor Yehuda Shoenfeld and Dr. Smadar Gertel from Sheba Medical Center, created synthetic peptides, including peptides comprising a plurality of epitopes, with each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues (Patented by Sheba Medical Center (US Patent 9,975,944 B2).
  • ZEUS Scientific intends to utilize these innovative multi-epitope citrullinated peptides for the development of a new generation of immunoassays designed to measure autoantibodies as an aid in the diagnosis of Rheumatoid Arthritis.
  • The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation.

Sheba Medical Center To Create 'Hospital Of The Future' Simulation Space Focusing On Digital Health And Home Healthcare As First Innovation Partner At SciTech Scity In Jersey City

Retrieved on: 
Friday, October 22, 2021
STEM, Science, Statue, Solution, Sheba Medical Center, Research, Tel Aviv University, Technology, City, Hospital, Liberty State Park, SciTech, Organization, Health equity, Partnership, Patient, Newsweek, ARC, Tuba City Regional Health Care Corporation, Communication, Liberty Science Center, Science and technology in Asia, Center, Life, LSC, CEO, MSR, Diabetes, Science center, LAH, Conditional sentence, Tel HaShomer, Health, COVID, Start-up Nation, AI, Student, Medicine, Pharmaceutical industry, Interior design

"Liberty ARC HealthSpace2030 complementsLiberty Science Center and SciTech Scity's mission to innovate and promote science and technology for all.

Key Points: 
  • "Liberty ARC HealthSpace2030 complementsLiberty Science Center and SciTech Scity's mission to innovate and promote science and technology for all.
  • Of particular note, Mr. Hoffman added that SciTech Scity and Liberty Science Center will assist Sheba in testing and introducing digital health and home health products in underserved communities in Jersey City and beyond.
  • And it is anticipated that new technologies, products, and companies emerging from the Liberty ARC HealthSpace2030 will create jobs in Jersey City.
  • The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation.

National Healthcare Staffing Agency Supports the Navajo Nation

Retrieved on: 
Thursday, September 3, 2020
Other Philanthropy, Human resources, Medical Supplies, Health, Infectious diseases, Hospitals, Professional services, Philanthropy, Geography of Arizona, Navajo history, Regions of the United States, States of the United States, Navajo Nation, Tuba City, Arizona, Flagstaff, Arizona, VISTA Staffing Solutions, Tuba City Regional Health Care Corporation

VISTA Staffing Solutions, Inc. a leading healthcare staffing agency, continues to give back to the communities where there is a desperate need for medical care and supplies.

Key Points: 
  • VISTA Staffing Solutions, Inc. a leading healthcare staffing agency, continues to give back to the communities where there is a desperate need for medical care and supplies.
  • Tuba serves the Navajo community 90 minutes outside of Flagstaff, Arizona," said Andrea Nelson, COO of VISTA Staffing Solutions.
  • As part of the staffing agency's commitment to supporting the Navajo Nation and TCRHCC, they have established a response and relief donation shopping link.
  • VISTA Staffing Solutions invites you to help the Navajo Nation and Tuba City Regional Health Care Corporation.